Published in BMC Endocr Disord on August 21, 2013
Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. Biochim Biophys Acta (2016) 0.83
Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem (1974) 15.45
Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med (2001) 11.92
Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol (2003) 6.78
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract (2005) 3.30
Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)--an introduction. Mol Nutr Food Res (2007) 2.56
Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol (2001) 2.10
Changes in BMI and weight before and after the development of type 2 diabetes. Diabetes Care (2001) 1.89
Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest (1998) 1.87
Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med (2007) 1.67
Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis (2005) 1.66
Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care (2009) 1.46
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia (2006) 1.32
Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin Biochem (2003) 1.32
Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem (2008) 1.28
Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin Biochem (2001) 1.28
RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab (2000) 1.24
The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol (2012) 1.12
Nitric oxide and ocular blood flow in patients with IDDM. Diabetes (1997) 1.11
Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci (2005) 1.10
Factors that influence improvement for patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract (2006) 1.07
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res (2007) 1.05
Lipid peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary heart disease. Diabetes Res Clin Pract (2001) 1.05
In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications (2000) 1.04
Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci (2004) 1.04
Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol (2005) 1.03
Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radic Biol Med (2007) 1.03
Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes. Regul Pept (2009) 1.00
The associations of body mass index, C-peptide and metabolic status in Chinese Type 2 diabetic patients. Diabet Med (2004) 0.98
Serum extracellular superoxide dismutase in patients with type 2 diabetes: relationship to the development of micro- and macrovascular complications. Diabetes Care (2003) 0.95
Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. Thromb Res (2010) 0.94
Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control. Arch Med Res (2001) 0.94
Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract (2002) 0.93
Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care (1998) 0.92
Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol (2000) 0.91
Methodological and preanalytical evaluation of a RAGE immunoassay. Anticancer Res (2012) 0.90
Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab (2000) 0.90
Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes. J Atheroscler Thromb (2002) 0.89
Short-term insulin therapy and normoglycemia. Effects on erythrocyte lipid peroxidation in NIDDM patients. Diabetes Care (1997) 0.88
Assay validation and biological variation of serum receptor for advanced glycation end-products. Ann Clin Biochem (2008) 0.88
Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Diabetes Res Clin Pract (2004) 0.87
Susceptibility of glutatione and glutathione-related antioxidant activity to hydrogen peroxide in patients with type 2 diabetes: effect of glycemic control. Clin Biochem (2002) 0.86
The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract (2003) 0.86
Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes. Eur J Pharmacol (2011) 0.85
Impaired synthesis is not the reason for decreased activity of extracellular superoxide dismutase in patients with diabetes. Arch Med Res (2005) 0.85
Differential nitric oxide levels in the blood and skeletal muscle of type 2 diabetic subjects may be consequence of adiposity: a preliminary study. Metabolism (2012) 0.84
Association between DNA strand breakage and oxidative, inflammatory and endothelial biomarkers in type 2 diabetes. Mutat Res (2012) 0.83
Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem (2007) 0.83
Association of oxidized low-density lipoprotein and transforming growth factor-beta in type 2 diabetic patients: a cross-sectional study. Transl Res (2008) 0.82
Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract (2004) 0.82
Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes. Arch Med Res (2011) 0.81
Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch Physiol Biochem (2008) 0.81
Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. Diabetes Res Clin Pract (2005) 0.81
Autoantibodies to oxidized low-density lipoprotein in patients with type 2 diabetes mellitus. Clin Chim Acta (2002) 0.78
No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. Clin Endocrinol (Oxf) (2006) 0.78
Effects of diabetes mellitus and acute hypertension on plasma nitric oxide and endothelin concentrations in rats. Clin Chim Acta (2002) 0.77
Impaired vasodilator response to atrial natriuretic factor in IDDM. Diabetes (1993) 0.76